SeaStar Medical Holding Corporation (ICU) Balance Sheet

The shift from a negative equity position to a positive one suggests that management has successfully utilized capital markets to repair the balance sheet, though this has come at the cost of significant shareholder dilution. Investors should monitor whether this trajectory can be sustained without further equity issuance, as the current equity base remains thin relative to the ongoing cash burn.

While the improvement in the current ratio indicates a temporary easing of immediate solvency pressures, the liquidity position remains highly sensitive to the pace of the NEUTRALIZE-AKI trial. The company appears to be operating with a narrow margin of safety, making it vulnerable to any unexpected delays in regulatory milestones or clinical data readouts.

The low leverage ratio suggests that the company is not currently burdened by interest expenses, which is a prudent strategy for a pre-profit entity. However, this lack of debt capacity may limit the company's ability to access non-dilutive financing, forcing a continued reliance on equity markets to sustain operations.